Printer Friendly

BIOGEN ANNOUNCES RESIGNATION OF DANIEL A. CUOCO, VICE PRESIDENT AND GENERAL COUNSEL

 CAMBRIDGE, Mass., June 3 /PRNewswire/ -- Biogen, Inc. (NASDAQ-NMS: BGEN), announced the resignation of Daniel A. Cuoco as vice president and general counsel. Cuoco resigned to pursue personal interests.
 Jim Vincent, Biogen's chairman, commented, "Some time ago, Dan told me he wanted to establish a different balance in his life between his career and personal goals. Dan is among the most experienced corporate counsels in the pharmaceutical industry and made a number of significant contributions to our company during his tenure. We will miss him at Biogen and wish him continued success in his future endeavors."
 Biogen, Inc. headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, and certain cancers.
 -0- 6/3/93
 /CONTACT: (media) Kathryn R. Bloom, director of communications, 617-252-9851; or (investment community) Amy S. Hedison, director, investor relations, 617-252-9873, both of Biogen, Inc./
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU: PER

DD -- NE008 -- 4897 06/03/93 10:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:209
Previous Article:FILENE'S BASEMENT REPORTS MAY SALES
Next Article:BET HOLDINGS, INC. REPORTS THIRD QUARTER RESULTS -- NET INCOME INCREASES 6 PERCENT ON REVENUE INCREASE OF 16 PERCENT
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
BIOGEN APPOINTS DANIEL A. CUOCO VICE PRESIDENT AND GENERAL COUNSEL
BIOGEN ANNOUNCES MANAGEMENT REALIGNMENT AS NEXT STEP IN TRANSITION FROM R&D ORGANIZATION TO OPERATING COMPANY
BIOGEN ANNOUNCES RESIGNATION OF DR. ROBERT J. GERETY, VICE PRESIDENT -DEVELOPMENT OPERATIONS
BIOGEN NAMES DANIEL B. MAGILAVY, M.D. AS DIRECTOR OF MEDICAL RESEARCH
BIOGEN NAMES ALAIN J. GILBERT AS VICE PRESIDENT-EUROPE
BIOGEN ANNOUNCES NEW MANAGEMENT APPOINTMENTS
BIOGEN APPOINTS HAROLD N. PRICE AS GENERAL MANAGER, RESEARCH TRIANGLE PARK
BIOGEN APPOINTS ALPHONSE R. NOE AS CHIEF INTELLECTUAL PROPERTY COUNSEL
BIOGEN APPOINTS THOMAS J. BUCKNUM AS CHIEF CORPORATE COUNSEL AND ASSOCIATE GENERAL COUNSEL

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters